-
Mashup Score: 33
Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+/CD8+) activation and helps overcome resistance to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors. We assessed efti plus pembrolizumab in second-line anti-PD-(L)1-refractory metastatic non-small cell lung cancer (NSCLC) patients.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Antibiotic use and survival in late-stage non-small cell lung cancer patients treated with chemo-immunotherapy - 9 month(s) ago
Immunotherapy has improved survival in patients with advanced non-small cell lung cancer (NSCLC). Efficacy may decrease when patients are treated with antibiotics, possibly due to gut microbiome disruption, but few studies have investigated this using real-world, patient-level populations in the United States.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Retrospective SEER analysis in #JTOCRR @JTOonline again shows negative association between antibiotic use and survival in pts with NSCLC receiving immunotherapy. Concern for impact on microbiome, though reason for antibiotics is a natural confounder. https://t.co/seurhqMizd
-
-
Mashup Score: 29
A 20-year-old man with metastatic large cell neuroendocrine carcinoma (LCNEC) of the lung was treated with the delta-like ligand 3 (DLL3) targeting bispecific T cell engager (BiTE), tarlatamab. Treatment was complicated by transient cytokine release syndrome (CRS) but resulted in a partial response. BiTEs may offer a novel treatment approach for LCNEC of the lung.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Case report in #JTOCRR @JTOonline of tarlatamab, a DLL3 bispecific T-cell engager (BiTE), in a 20 year old patient with large cell neuroendocrine carcinoma and prior chemo-immunotherapy. Developed G3 CRS but recovered and had a partial response x 6m. https://t.co/QbtwdNpSUa
-
-
Mashup Score: 39
The available approved anti-cancer drugs for Chinese patients are relatively limited because of China’s low participation rate in international clinical trials. Therefore, a focus on approved anti-PD-1/PD-L1 drugs in China is needed. This study aims to assess the heterogeneity of anti-PD-1/PD-L1 antibodies manufactured in China (domestic PD-1/PD-L1) and overseas (imported PD-1/PD-L1) when combined with chemotherapy as the first-line treatment of NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Review & meta-analysis of 1L PD(L)1 plus chemo for NSCLC in China #JTOCRR @JTOonline. No difference in OS or PFS between domestic (camrelizumab, sintilimab, sugemalimab, tislelizumab, toripalimab) & imported (atezolizumab, pembrolizumab, durvalumab). https://t.co/Hwy8SRCb6A
-
-
Mashup Score: 19Harnessing Opportunity: Pilot Intervention to Improve Lung Cancer Screening for Women Undergoing Breast Screening Mammography - 1 year(s) ago
The screening mammogram could be a “teachable moment” to improve lung cancer screening (LCS) uptake. The aim of our project was to combine patient self-referral with eligibility identification by providers as a two-pronged approach to increase rates of LCS among eligible women.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Report on a pilot intervention to inform women undergoing screening mammography about lung cancer screening in #JTOCRR @JTOonline. Patients were responsive to learning about dual screening - important efforts from Drs. @LyeYengWongMD @leahbackhusmd https://t.co/qmiPMedRUW
-
-
Mashup Score: 51Brief Report: Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC - 1 year(s) ago
Previous studies reported an association between immune checkpoint inhibitor (ICI) infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Another retrospective report linking timing of immunotherapy administration in NSCLC to outcomes in #JTOCRR. Here, pts receiving durvalumab consolidation after chemoradiation had worse PFS/OS if at least 20% of their infusions were after 3pm. @JTOonline https://t.co/dBfBmFFJU4
-
-
Mashup Score: 38The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) Non-Small Cell Lung Cancer: A Nationwide Analysis - 1 year(s) ago
Multiple clinical trials have shown the benefit of immunotherapy (IO) for non-small cell lung cancer (NSCLC), including unresectable stage III disease. Our aim was to investigate the impact of IO use on treatment and outcomes of potentially resectable stage IIIA NSCLC in a broader nationwide patient cohort.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Interesting to see how PACIFIC influenced practice. Report #JTOCRR shows in stage IIIA NSCLC, IO uncommon until 2017 but up to 40% by 2019. That increase was associated with more use of chemoradiation and a decrease in surgery for IIIA. https://t.co/pvj9ujA2Br
-
-
Mashup Score: 19Health services access inequalities in Brazil result in poorer outcomes for stage III NSCLC - RELANCE/LACOG 0118 - 1 year(s) ago
Stage III NSCLC is a heterogeneous disease, representing around one-third of newly diagnosed lung cancers. Brazil lacks detailed information regarding stage distribution, treatment patterns, survival, and prognostic variables in locally advanced NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Social determinants of health continue to play a major role in cancer care. Results from retrospective RELANCE/LACOG 0118 study on stage III NSCLC in Brazil #JTOCRR. In 403 pts, type of health insurance was independent predictor of survival. @JTOonline https://t.co/AGLACVuGvZ
-
-
Mashup Score: 36
Biomarker testing in oncology is fundamental for targeted therapy use and clinical trial participation. Factors contributing to previously identified racial disparities in biomarker testing remain unclear. This study investigated biomarker testing, clinical trial participation and targeted therapy by race among patients with metastatic lung cancer with Medicaid coverage in the U.S.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Real world Medicaid database study on biomarker testing in lung cancer from Dr. @DeboraBrunoMD1 #JTOCRR @JTOonline. In 3845 US pts from 2017-19, biomarker testing done in 57%, targeted therapy given to 4.6%, clinical trial participation in only 2.6%. https://t.co/NH9GbgNAM7
-
-
Mashup Score: 37The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in Non-Small Cell Lung Cancer Treated with Atezolizumab - 1 year(s) ago
Immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICIs) can have complicated clinical courses. We comprehensively evaluated the timing, trajectory, and incidence of both single and multiple irAEs for non-small cell lung cancer (NSCLC) treated with atezolizumab.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet-
Pooled analysis describing adverse events with atezolizumab (PDL1 inhibitor) in NSCLC now in #JTOCRR @JTOonline. Included 2457 pts from IMpower 130, 132, and 150. Helpful breakdown of timing of irAEs as it varies by specific AE. https://t.co/2IgDUKQxyz
-
Phase II study of 2L soluble LAG3 protein Eftilagimod Alpha with pembrolizumab in NSCLC in #JTOCRR @JTOonline (n=36). RR 8.3%, DCR 33.3%, mPFS 2.1m, mOS 9.9m with better outcomes in PD-L1 high. Very difficult to interpret post-IO given heterogeneity. https://t.co/cjqXOKcAg3